An abbreviated version of the Brain Care Score predicts risk for dementia, stroke, and late-life depression based on lifestyle factors alone.

Glucagon-like peptide-1 receptor agonist therapy is associated with a reduced risk for epilepsy in adults with type 2 diabetes mellitus.

Suzanna's Kitchen breaded chicken has been recalled after soy, a major allergen, was not identified on the packaging.

New recommendations focused on psychological intervention may help manage or reduce the impact of functional seizures.

Among women with fibromyalgia, overactive bladder is prevalent and may often be associated with higher symptom severity and comorbidity.

The FDA has granted Fast Track designation to ST-503 for the treatment of small fiber neuropathy, a chronic neuropathic pain disorder.

The FDA has approved Uplizna for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive.

Artificial intelligence-enabled point-of-care EEG allows rapid bedside seizure detection, accelerating treatment and preventing unnecessary care escalation.

Baseline neuropsychiatric profiles in older adults stratify future cognitive decline, neuropathology, and risk for MCI or dementia.

Cognitive impairment is positively associated with neuropsychiatric symptoms in both individuals with Down syndrome and older adults without Down syndrome.

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

Ginkgo biloba and several other therapies offer modest cognitive benefits in vascular cognitive impairment, but heterogeneous evidence limits certainty.